Want to see LYEL full AI Analyst Report?
LYEL Stock Chart & Stats
$12.63
-$0.15(-1.17%)
At close: 4:00 PM EDT
$12.63
-$0.15(-1.17%)
Day’s Range― - ―
52-Week Range$10.49 - $45.00
Previous Close$12.63
Volume90.65K
Average Volume (3M)74.95K
Market Cap
$386.94M
Enterprise Value$170.76
Total Cash (Recent Filing)$204.10M
Total Debt (Recent Filing)$36.93M
Price to Earnings (P/E)―
Beta2.05
Next Earnings
Nov 10, 2026EPS Estimate
-2.05Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-16.01
Shares Outstanding24,505,140
10 Day Avg. Volume75,611
30 Day Avg. Volume74,954
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)2.12
Price to Sales (P/S)14614.51
P/FCF Ratio-3.49
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$36.20Price Target Upside186.62% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering5
EPS Forecast (FY)-7.28
Revenue Forecast (FY)$10.00K
Bulls Say, Bears Say
Bulls Say
Low Leverage / Conservative Balance SheetRelatively light debt reduces near-term refinancing and interest burden risk, giving management durable financial flexibility to fund clinical programs. For a cash-burning biotech, low leverage helps preserve optionality for partnerships, licensing or less-dilutive financings over the next 2–6 months.
Cash Runway Into Q3 2027A stated cash balance sufficient into Q3 2027 materially reduces immediate pressure to raise capital, enabling continued clinical development and milestone-driven value creation. This runway supports execution of trials and business development without urgent dilutive financings in the medium term.
Next‑gen T‑cell Platform And PipelineA platform-focused strategy (T-cell engineering, CAR T and TCR programs, manufacturing tech) offers scalable long-term advantages if it improves durability/function in tumors. Platform IP and manufacturing capabilities can lead to durable differentiation, partnerships and multiple downstream value streams.
Bears Say
High Operating Cash BurnSustained, large negative operating and free cash flow consumes cash reserves and increases the likelihood of future equity raises or partnership dependence. Heavy burn constrains strategic choices, can force dilutive financing, and raises execution risk if clinical timelines slip or expenses rise.
Minimal Revenue And Persistent Large LossesWith essentially no product revenue and substantial net losses, the company remains reliant on external funding and collaboration payments. This lack of operating revenue undermines long-term self-sufficiency and increases vulnerability to capital-market conditions over the next several quarters.
Capital Erosion And Negative ReturnsDeclining equity and a deeply negative ROE indicate cumulative value destruction from operating losses. Continued capital erosion weakens balance-sheet resilience, may impair bargaining power with partners, and raises governance and financing risks over the medium term.
Lyell Immunopharma News
LYEL FAQ
What was Lyell Immunopharma’s price range in the past 12 months?
Lyell Immunopharma lowest stock price was $10.49 and its highest was $45.00 in the past 12 months.
What is Lyell Immunopharma’s market cap?
Lyell Immunopharma’s market cap is $386.94M.
When is Lyell Immunopharma’s upcoming earnings report date?
Lyell Immunopharma’s upcoming earnings report date is Nov 10, 2026 which is in 81 days.
How were Lyell Immunopharma’s earnings last quarter?
Lyell Immunopharma released its earnings results on Aug 12, 2026. The company reported -$1.92 earnings per share for the quarter, missing the consensus estimate of -$1.9 by -$0.02.
Is Lyell Immunopharma overvalued?
According to Wall Street analysts Lyell Immunopharma’s price is currently Undervalued.
Does Lyell Immunopharma pay dividends?
Lyell Immunopharma does not currently pay dividends.
What is Lyell Immunopharma’s EPS estimate?
Lyell Immunopharma’s EPS estimate is -2.05.
How many shares outstanding does Lyell Immunopharma have?
Lyell Immunopharma has 24,505,140 shares outstanding.
What happened to Lyell Immunopharma’s price movement after its last earnings report?
Lyell Immunopharma reported an EPS of -$1.92 in its last earnings report, missing expectations of -$1.9. Following the earnings report the stock price went down -3.035%.
Which hedge fund is a major shareholder of Lyell Immunopharma?
Currently, no hedge funds are holding shares in LYEL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Lyell Immunopharma Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$36.20 (186.62% Upside)
$36.20 (186.62% Upside)
Blogger Sentiment
Bullish
LYEL Sentiment 80%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 98.4K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $29.4K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
106.67%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-19.28%
Trailing 12-Months
Company Description
Lyell Immunopharma
Lyell Immunopharma, Inc. (LYEL) is a clinical-stage biotechnology company focused on developing next-generation T cell therapies for cancer. The company applies cell engineering approaches intended to enhance the durability and function of T cells in the tumor microenvironment, with a pipeline that includes programs in adoptive cell therapy (such as CAR T and TCR-based therapies) and related technology platforms for T-cell reprogramming/manufacturing.
LYEL Stock 12 Month Forecast
Average Price Target
$36.20
▲(186.62% Upside)
Technical Analysis
Rocket Pharmaceuticals
―
Editas Medicine
―
Mereo Biopharma Group Plc
―
Replimune Group
―
―
Ownership Overview
39.41% Insiders
6.98% Mutual Funds
32.69% Other Institutional Investors
14.88% Public Companies and
Individual Investors